Strong Growth in Keytruda Revenue Contrasts with Decline in Gardasil Sales in China Amid Economic and Regulatory Challenges
Merck & Co (MRK) has posted better-than-expected third-quarter earnings, supported by robust sales of its flagship cancer drug Keytruda. However, the pharmaceutical giant continues to face challenges with its Gardasil vaccine in China, marking the second consecutive quarter of reduced demand in the region. While Keytruda’s performance has been a significant revenue driver for Merck, Gardasil’s slump in the Chinese market raises concerns for one of Merck’s fastest-growing vaccines outside oncology.
For Q3, Merck reported earnings of $3.99 billion, or $1.57 per share, exceeding analysts’ projections of $1.50 per share, according to LSEG data. Total sales rose 4% to reach $16.66 billion, also surpassing analyst estimates of $16.45 billion. Notably, Keytruda sales surged 17% to $7.43 billion, surpassing Wall Street’s $7.20 billion target. Keytruda’s robust sales underscore its role as a central component of Merck’s revenue strategy, especially as the company continues to face hurdles with Gardasil in certain markets.
Gardasil, a vaccine that prevents cancers linked to the human papillomavirus (HPV), has been a strong performer for Merck, particularly in China, where demand had previously fueled international growth. However, Gardasil sales declined by 11% this quarter, falling to $2.31 billion, missing analyst expectations of $2.46 billion. This drop marks another challenging quarter for Gardasil in China, following similar issues in Q2. CEO Rob Davis attributed the decrease to a combination of economic pressures, shifts in promotional activity, and adjustments in inventory, particularly as Chinese authorities intensify efforts to combat corruption within the healthcare sector. These anti-corruption initiatives have impacted Merck’s business dealings with hospitals and disrupted the usual channels of distribution and promotion for Gardasil.
“Ultimately, what we have to do is drive demand,” Davis stated, emphasizing the company’s long-term commitment to boosting Gardasil’s market presence in China. Merck’s optimism about Gardasil’s potential in the region remains undeterred. According to Davis, there is still significant room for growth, with a sizable population of women eligible for the vaccine and a potential opportunity to expand to men. Outside of China, Merck reports “double-digit growth in almost every other major region,” further highlighting Gardasil’s global traction despite localized setbacks.
Merck’s Gardasil forecast reflects the company’s expectations for long-term success. While Gardasil sales have more than doubled since 2020, the company remains committed to reaching its global sales goal of $11 billion by 2030. Despite the ongoing challenges in China, Merck sees this target as achievable with Gardasil’s continued growth in other regions.
Merck’s third-quarter report also comes amid broader struggles for vaccines in China, as demonstrated by GSK’s recent disclosure that its shingles vaccine, Shingrix, also experienced sales declines in the region. These difficulties underline the complexities of operating in the Chinese healthcare market, where economic fluctuations and regulatory scrutiny pose ongoing risks for international pharmaceutical companies.
Merck’s stock closed at $104.83 on Wednesday, having declined approximately 7% year-to-date. This performance contrasts with the S&P 500, which has risen over 22% within the same period. Despite the dip in share value, Merck’s quarterly performance, driven by Keytruda’s success, reinforces its strategic focus on oncology while acknowledging the need to address regional challenges for Gardasil’s expansion in China.
You might like this article:Roku Surpasses $1 Billion in Q3 Revenue, Boosted by Platform and Device Success
